- Home
- NSIT vs TSHA Comparison
NSIT vs TSHA Comparison
Compare NSIT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSIT | TSHA |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NSIT | TSHA |
|---|---|---|
| Price | $111.80 | $6.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $116.25 | $11.63 |
| AVG Volume (30 Days) | 442.7K | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $8,247,180,000.00 | $9,773,000.00 |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $2.16 | $1,152.42 |
| P/E Ratio | $115.61 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $63.62 | $2.34 |
| 52 Week High | $148.36 | $7.30 |
Technical Indicators
Market Signals| Indicator | NSIT | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 52.54 |
| Support Level | $104.68 | $6.11 |
| Resistance Level | $112.95 | $7.06 |
| Average True Range (ATR) | 5.25 | 0.41 |
| MACD | -1.20 | -0.01 |
| Stochastic Oscillator | 41.86 | 38.93 |
Price Performance
Historical ComparisonAbout NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.